Skip to main content
PMC home page
Nucleic Acids Research logoLink to Nucleic Acids Research
. 1999 Aug 1;27(15):3159–3167. doi: 10.1093/nar/27.15.3159

Inhibition of luciferase expression by synthetic hammerhead ribozymes and their cellular uptake.

B Bramlage 1, S Alefelder 1, P Marschall 1, F Eckstein 1
PMCID: PMC148543  PMID: 10454613

Abstract

Two synthetic hammerhead ribozymes, one unmodified and the other with 2"-modifications and four phosphorothioate groups, targeting a single GUA site in the luciferase mRNA, were compared for their inhibition of gene expression in cell cultureand their cellular uptake was also analysed. A HeLa X1/5 cell line stably expressing luciferase, under an inducible promoter, was treated with these ribozymes by liposome-mediated transfection to determine their activity.Luciferase expression in cells was inhibited to approximately 50% with little difference between the unmodified and the 2"-modified ribozyme. A similar degree of inhibition was observed with two catalytically inactive ribozymes, indicating that inhibition was mainly due to an antisense effect. A ribozyme carrying a cholesterol moiety, applied to the cells without carrier, showed no inhibition. Northern blotting indicated a similar amount of cellular uptake of all ribozymes. The unmodified ribozyme was essentially evenly distributed between cytoplasm and nucleus, whereas a higher proportion of the phosphorothioate-containing ribozyme was observed in the nucleus. Fluorescence microscopy, including confocal microscopy using 5"-fluorescein-labelled ribozymes, showed that the unmodified and 2"-modified ribozymes were present in the cytoplasm and in the nucleus to a similar extent, whereas the fluorescence of the phosphorothioate-containing ribozyme was much stronger in the nucleus. Both ribozymes inhibited luciferase expression to a comparable degree, suggesting that the ribozyme in the nucleus did not contribute significantly to the inhibition. Ribozymes with a cholesterol moiety were predominantly trapped in the cell membrane, explaining their inability to interfere with gene expression.

Full Text

The Full Text of this article is available as a PDF (756.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alahari S. K., Dean N. M., Fisher M. H., Delong R., Manoharan M., Tivel K. L., Juliano R. L. Inhibition of expression of the multidrug resistance-associated P-glycoprotein of by phosphorothioate and 5' cholesterol-conjugated phosphorothioate antisense oligonucleotides. Mol Pharmacol. 1996 Oct;50(4):808–819. [PubMed] [Google Scholar]
  2. Aurup H., Siebert A., Benseler F., Williams D., Eckstein F. Translation of 2'-modified mRNA in vitro and in vivo. Nucleic Acids Res. 1994 Nov 25;22(23):4963–4968. doi: 10.1093/nar/22.23.4963. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bertrand E., Castanotto D., Zhou C., Carbonnelle C., Lee N. S., Good P., Chatterjee S., Grange T., Pictet R., Kohn D. The expression cassette determines the functional activity of ribozymes in mammalian cells by controlling their intracellular localization. RNA. 1997 Jan;3(1):75–88. [PMC free article] [PubMed] [Google Scholar]
  4. Birikh K. R., Heaton P. A., Eckstein F. The structure, function and application of the hammerhead ribozyme. Eur J Biochem. 1997 Apr 1;245(1):1–16. doi: 10.1111/j.1432-1033.1997.t01-3-00001.x. [DOI] [PubMed] [Google Scholar]
  5. Bramlage B., Luzi E., Eckstein F. Designing ribozymes for the inhibition of gene expression. Trends Biotechnol. 1998 Oct;16(10):434–438. doi: 10.1016/s0167-7799(98)01236-0. [DOI] [PubMed] [Google Scholar]
  6. Citti L., Eckstein F., Capecchi B., Mariani L., Nevischi S., Poggi A., Rainaldi G. Transient transfection of a synthetic hammerhead ribozyme targeted against human MGMT gene to cells in culture potentiates the genotoxicity of the alkylation damage induced by mitozolomide. Antisense Nucleic Acid Drug Dev. 1999 Apr;9(2):125–133. doi: 10.1089/oli.1.1999.9.125. [DOI] [PubMed] [Google Scholar]
  7. Clarenc J. P., Degols G., Leonetti J. P., Milhaud P., Lebleu B. Delivery of antisense oligonucleotides by poly(L-lysine) conjugation and liposome encapsulation. Anticancer Drug Des. 1993 Feb;8(1):81–94. [PubMed] [Google Scholar]
  8. Dorai T., Goluboff E. T., Olsson C. A., Buttyan R. Development of a hammerhead ribozyme against BCL-2. II. Ribozyme treatment sensitizes hormone-resistant prostate cancer cells to apoptotic agents. Anticancer Res. 1997 Sep-Oct;17(5A):3307–3312. [PubMed] [Google Scholar]
  9. Epa W. R., Rong P., Bartlett P. F., Coulson E. J., Barrett G. L. Enhanced downregulation of the p75 nerve growth factor receptor by cholesteryl and bis-cholesteryl antisense oligonucleotides. Antisense Nucleic Acid Drug Dev. 1998 Dec;8(6):489–498. doi: 10.1089/oli.1.1998.8.489. [DOI] [PubMed] [Google Scholar]
  10. Fell P. L., Hudson A. J., Reynolds M. A., Usman N., Akhtar S. Cellular uptake properties of a 2'-amino/2'-O-methyl-modified chimeric hammerhead ribozyme targeted to the epidermal growth factor receptor mRNA. Antisense Nucleic Acid Drug Dev. 1997 Aug;7(4):319–326. doi: 10.1089/oli.1.1997.7.319. [DOI] [PubMed] [Google Scholar]
  11. Flores M. V., Atkins D., Wade D., O'Sullivan W. J., Stewart T. S. Inhibition of Plasmodium falciparum proliferation in vitro by ribozymes. J Biol Chem. 1997 Jul 4;272(27):16940–16945. doi: 10.1074/jbc.272.27.16940. [DOI] [PubMed] [Google Scholar]
  12. Flory C. M., Pavco P. A., Jarvis T. C., Lesch M. E., Wincott F. E., Beigelman L., Hunt S. W., 3rd, Schrier D. J. Nuclease-resistant ribozymes decrease stromelysin mRNA levels in rabbit synovium following exogenous delivery to the knee joint. Proc Natl Acad Sci U S A. 1996 Jan 23;93(2):754–758. doi: 10.1073/pnas.93.2.754. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Gossen M., Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5547–5551. doi: 10.1073/pnas.89.12.5547. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Gu J. L., Nadler J., Rossi J. Use of a hammerhead ribozyme with cationic liposomes to reduce leukocyte type 12-lipoxygenase expression in vascular smooth muscle. Mol Cell Biochem. 1997 Jul;172(1-2):47–57. [PubMed] [Google Scholar]
  15. Heidenreich O., Benseler F., Fahrenholz A., Eckstein F. High activity and stability of hammerhead ribozymes containing 2'-modified pyrimidine nucleosides and phosphorothioates. J Biol Chem. 1994 Jan 21;269(3):2131–2138. [PubMed] [Google Scholar]
  16. Hope M. J., Mui B., Ansell S., Ahkong Q. F. Cationic lipids, phosphatidylethanolamine and the intracellular delivery of polymeric, nucleic acid-based drugs (review). Mol Membr Biol. 1998 Jan-Mar;15(1):1–14. doi: 10.3109/09687689809027512. [DOI] [PubMed] [Google Scholar]
  17. Hormes R., Homann M., Oelze I., Marschall P., Tabler M., Eckstein F., Sczakiel G. The subcellular localization and length of hammerhead ribozymes determine efficacy in human cells. Nucleic Acids Res. 1997 Feb 15;25(4):769–775. doi: 10.1093/nar/25.4.769. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Jarvis T. C., Alby L. J., Beaudry A. A., Wincott F. E., Beigelman L., McSwiggen J. A., Usman N., Stinchcomb D. T. Inhibition of vascular smooth muscle cell proliferation by ribozymes that cleave c-myb mRNA. RNA. 1996 May;2(5):419–428. [PMC free article] [PubMed] [Google Scholar]
  19. Jarvis T. C., Wincott F. E., Alby L. J., McSwiggen J. A., Beigelman L., Gustofson J., DiRenzo A., Levy K., Arthur M., Matulic-Adamic J. Optimizing the cell efficacy of synthetic ribozymes. Site selection and chemical modifications of ribozymes targeting the proto-oncogene c-myb. J Biol Chem. 1996 Nov 15;271(46):29107–29112. doi: 10.1074/jbc.271.46.29107. [DOI] [PubMed] [Google Scholar]
  20. Kitajima I., Hanyu N., Soejima Y., Hirano R., Arahira S., Yamaoka S., Yamada R., Maruyama I., Kaneda Y. Efficient transfer of synthetic ribozymes into cells using hemagglutinating virus of Japan (HVJ)-cationic liposomes. Application for ribozymes that target human t-cell leukemia virus type I tax/rex mRNA. J Biol Chem. 1997 Oct 24;272(43):27099–27106. doi: 10.1074/jbc.272.43.27099. [DOI] [PubMed] [Google Scholar]
  21. Konopka K., Rossi J. J., Swiderski P., Slepushkin V. A., Düzgüneş N. Delivery of an anti-HIV-1 ribozyme into HIV-infected cells via cationic liposomes. Biochim Biophys Acta. 1998 Jun 24;1372(1):55–68. doi: 10.1016/s0005-2736(98)00046-7. [DOI] [PubMed] [Google Scholar]
  22. Krieg A. M., Tonkinson J., Matson S., Zhao Q., Saxon M., Zhang L. M., Bhanja U., Yakubov L., Stein C. A. Modification of antisense phosphodiester oligodeoxynucleotides by a 5' cholesteryl moiety increases cellular association and improves efficacy. Proc Natl Acad Sci U S A. 1993 Feb 1;90(3):1048–1052. doi: 10.1073/pnas.90.3.1048. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Lange W. Cleavage of BCR/ABL mRNA by synthetic ribozymes--effects on the proliferation rate of K562 cells. Klin Padiatr. 1995 Jul-Aug;207(4):222–224. doi: 10.1055/s-2008-1046544. [DOI] [PubMed] [Google Scholar]
  24. Letsinger R. L., Zhang G. R., Sun D. K., Ikeuchi T., Sarin P. S. Cholesteryl-conjugated oligonucleotides: synthesis, properties, and activity as inhibitors of replication of human immunodeficiency virus in cell culture. Proc Natl Acad Sci U S A. 1989 Sep;86(17):6553–6556. doi: 10.1073/pnas.86.17.6553. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Lyngstadaas S. P., Risnes S., Sproat B. S., Thrane P. S., Prydz H. P. A synthetic, chemically modified ribozyme eliminates amelogenin, the major translation product in developing mouse enamel in vivo. EMBO J. 1995 Nov 1;14(21):5224–5229. doi: 10.1002/j.1460-2075.1995.tb00207.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Matsushita H., Kobayashi H., Mori S., Kizaki M., Ikeda Y. Ribozymes cleave the AML1/MTG8 fusion transcript and inhibit proliferation of leukemic cells with t(8;21). Biochem Biophys Res Commun. 1995 Oct 13;215(2):431–437. doi: 10.1006/bbrc.1995.2483. [DOI] [PubMed] [Google Scholar]
  27. Prasmickaite L., Hogset A., Maelandsmo G., Berg K., Goodchild J., Perkins T., Fodstad O., Hovig E. Intracellular metabolism of a 2'-O-methyl-stabilized ribozyme after uptake by DOTAP transfection or asfree ribozyme. A study by capillary electrophoresis. Nucleic Acids Res. 1998 Sep 15;26(18):4241–4248. doi: 10.1093/nar/26.18.4241. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Rossi J. J. Therapeutic ribozymes: principles and applications. BioDrugs. 1998 Jan;9(1):1–10. doi: 10.2165/00063030-199809010-00001. [DOI] [PubMed] [Google Scholar]
  29. Scherr M., Grez M., Ganser A., Engels J. W. Specific hammerhead ribozyme-mediated cleavage of mutant N-ras mRNA in vitro and ex vivo. Oligoribonucleotides as therapeutic agents. J Biol Chem. 1997 May 30;272(22):14304–14313. doi: 10.1074/jbc.272.22.14304. [DOI] [PubMed] [Google Scholar]
  30. Shoji Y., Ishige H., Tamura N., Iwatani W., Norimatsu M., Shimada J., Mizushima Y. Enhancement of anti-herpetic activity of antisense phosphorothioate oligonucleotides 5' end modified with geraniol. J Drug Target. 1998;5(4):261–273. doi: 10.3109/10611869808995880. [DOI] [PubMed] [Google Scholar]
  31. Sigurdson S. T., Eckstein F. Site specific labelling of sugar residues in oligoribonucleotides: reactions of aliphatic isocyanates with 2' amino groups. Nucleic Acids Res. 1996 Aug 15;24(16):3129–3133. doi: 10.1093/nar/24.16.3129. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Sigurdsson Snorri Th., Seeger Bodo, Kutzke Ursula, Eckstein Fritz. A Mild and Simple Method for the Preparation of Isocyanates from Aliphatic Amines Using Trichloromethyl Chloroformate. Synthesis of an Isocyanate Containing an Activated Disulfide. J Org Chem. 1996 May 31;61(11):3883–3884. doi: 10.1021/jo9521920. [DOI] [PubMed] [Google Scholar]
  33. Sioud M. Effects of variations in length of hammerhead ribozyme antisense arms upon the cleavage of longer RNA substrates. Nucleic Acids Res. 1997 Jan 15;25(2):333–338. doi: 10.1093/nar/25.2.333. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Sioud M. Ribozyme modulation of lipopolysaccharide-induced tumor necrosis factor-alpha production by peritoneal cells in vitro and in vivo. Eur J Immunol. 1996 May;26(5):1026–1031. doi: 10.1002/eji.1830260511. [DOI] [PubMed] [Google Scholar]
  35. Sioud M., Sørensen D. R. A nuclease-resistant protein kinase C alpha ribozyme blocks glioma cell growth. Nat Biotechnol. 1998 Jun;16(6):556–561. doi: 10.1038/nbt0698-556. [DOI] [PubMed] [Google Scholar]
  36. Snyder D. S., Wu Y., Wang J. L., Rossi J. J., Swiderski P., Kaplan B. E., Forman S. J. Ribozyme-mediated inhibition of bcr-abl gene expression in a Philadelphia chromosome-positive cell line. Blood. 1993 Jul 15;82(2):600–605. [PubMed] [Google Scholar]
  37. Stein C. A., Pal R., DeVico A. L., Hoke G., Mumbauer S., Kinstler O., Sarngadharan M. G., Letsinger R. L. Mode of action of 5'-linked cholesteryl phosphorothioate oligodeoxynucleotides in inhibiting syncytia formation and infection by HIV-1 and HIV-2 in vitro. Biochemistry. 1991 Mar 5;30(9):2439–2444. doi: 10.1021/bi00223a020. [DOI] [PubMed] [Google Scholar]
  38. Thierry A. R., Dritschilo A. Intracellular availability of unmodified, phosphorothioated and liposomally encapsulated oligodeoxynucleotides for antisense activity. Nucleic Acids Res. 1992 Nov 11;20(21):5691–5698. doi: 10.1093/nar/20.21.5691. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Wang Q., Mullah B., Hansen C., Asundi J., Robishaw J. D. Ribozyme-mediated suppression of the G protein gamma7 subunit suggests a role in hormone regulation of adenylylcyclase activity. J Biol Chem. 1997 Oct 10;272(41):26040–26048. doi: 10.1074/jbc.272.41.26040. [DOI] [PubMed] [Google Scholar]
  40. Wingens M., van Hooijdonk C. A., de Jongh G. J., Schalkwijk J., van Erp P. E. Flow cytometric and microscopic characterization of the uptake and distribution of phosphorothioate oligonucleotides in human keratinocytes. Arch Dermatol Res. 1998 Mar;290(3):119–125. doi: 10.1007/s004030050276. [DOI] [PubMed] [Google Scholar]
  41. Xie Y., Chen X., Wagner T. E. A ribozyme-mediated, gene "knockdown" strategy for the identification of gene function in zebrafish. Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13777–13781. doi: 10.1073/pnas.94.25.13777. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Zelphati O., Wagner E., Leserman L. Synthesis and anti-HIV activity of thiocholesteryl-coupled phosphodiester antisense oligonucleotides incorporated into immunoliposomes. Antiviral Res. 1994 Sep;25(1):13–25. doi: 10.1016/0166-3542(94)90090-6. [DOI] [PubMed] [Google Scholar]
  43. Zhang X., Iwatani Y., Shimayama T., Yamada R., Koito A., Xu Y., Sakai H., Uchiyama T., Hattori T. Phosphorothioate hammerhead ribozymes targeting a conserved sequence in the V3 loop region inhibit HIV-1 entry. Antisense Nucleic Acid Drug Dev. 1998 Dec;8(6):441–450. doi: 10.1089/oli.1.1998.8.441. [DOI] [PubMed] [Google Scholar]
  44. Zhang X., Yamada R., Shimayama T., Imada K., Uchiyama T., Hattori T. Phosphorothiolate ribozyme against the conserved sequence in V3 loop of HIV-1. Biochem Biophys Res Commun. 1996 Dec 13;229(2):466–471. doi: 10.1006/bbrc.1996.1827. [DOI] [PubMed] [Google Scholar]

Articles from Nucleic Acids Research are provided here courtesy of Oxford University Press

RESOURCES